The lines between “traditional” medicine and “digital” health are no longer blurring; they are disappearing. Today, the future of care lies at the precise intersection of biology, technology, and data.

We are excited to announce that Newel Health will be attending BioTechX Europe 2025, taking place in Basel, Switzerland, from October 6–8.

As Europe’s largest congress for diagnostics, precision medicine, and digital transformation in pharmaceutical development, BioTechX attracts over 3,000 industry leaders, 400 speakers, and 150 exhibitors. For us, Basel—often considered the heart of the European pharmaceutical industry—is the perfect backdrop to discuss the next evolution of chronic disease management.

Why We Are Going: The Digital-Pharma Convergence

We are attending not just as tech innovators, but as a legal manufacturer of digital therapeutics (DTx).

This distinction is crucial. In an event focused heavily on data and AI, we bring the perspective of a company that translates these technologies into regulated medical devices. We are looking forward to joining critical conversations on:

• Precision Medicine: Moving beyond the pill to understand how digital biomarkers can predict patient needs.
• Data & AI: innovative uses of Artificial Intelligence—driven by our H. Core platform—to personalize treatment pathways in real-time.
• The “Beyond the Pill” Strategy: Exploring how digital companions can enhance the efficacy of traditional pharmacotherapies.

Collaboration is the Cure

No single entity can solve the crisis of chronic disease alone.

At Newel Health, we believe the most impactful solutions arise when Pharma, Healthcare Systems, and Digital Health companies align their incentives. We are in Basel to forge partnerships that bridge these silos. We want to discuss how digital therapeutics can be integrated into the broader pharmaceutical value chain, from clinical trials to market access.

Connect with Us in Basel

Our CEO, Ervin Ukaj, will be on the ground representing the Newel Health team.

If you are a pharmaceutical partner, a healthcare provider, or a fellow innovator who shares our vision of making digital therapeutics integral to standard care, we want to meet you. Let’s discuss how we can collaborate to deliver meaningful, data-driven impact for patients.

Will you be in Basel? Reach out to connect with Ervin and let’s shape the future of hybrid care together.